Lee S. Schwartzberg MD, FACP
Medical Director, West Cancer Center, Memphis, Tennessee; Chief Medical Officer, OneOncologyLee S. Schwartzberg, MD, FACP, is the Medical Director of the West Cancer Center, a multispecialty oncology practice comprising over 60 medical oncologists, gynecologic oncologists, radiation oncologists, surgical oncologists, palliative care experts, radiologists and other oncology related physicians located in Memphis, Tennessee. In 2019, Dr. Schwartzberg became Chief Medical Officer for OneOncology, a national partnership of independent community oncology practices. He also serves as Professor of Medicine at The University of Tennessee Health Science Center.
Dr. Schwartzberg received his medical degree from New York Medical College. After completing his internal medicine residency at Cornell University/North Shore University Hospital, Dr. Schwartzberg continued his training with a medical oncology and hematology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). During his tenure at MSKCC, Dr. Schwartzberg served as Chief Medical Resident and was a founding member of the institutional ethics committee.
Dr. Schwartzberg specializes in the treatment of breast cancer, with a specific research focus on new therapeutic approaches, targeted therapy, and supportive care. Dr. Schwartzberg has published more than 240 peer reviewed articles in peer-reviewed journals, including Journal of Clinical Oncology, The Lancet Oncology, and Annals of Oncology.
Dr. Schwartzberg was the founding editor-in-chief of the journal Community Oncology and currently serves as the editor-in-chief of the PracticeUpdate Oncology website. He serves on the editorial board of both the Journal of Supportive Oncology and the ASCO Post, in addition to serving as a reviewer for many prominent medical journals, including the New England Journal of Medicine and Journal of Clinical Oncology. Dr. Schwartzberg served on the NCCN Board of Directors and the NCCN Guidelines Steering Committee for many years.
Positions:
Medical Director, West Cancer Center, Memphis, Tennessee
Chief Medical Officer, OneOncology
Degrees:
State University of New York, BA and MS
New York Medical College, MD, FACP
Postgraduate Training:
Intern, North Shore University Hospital, Manhasset, NY
Fellow in medical oncology/hematology, Memorial Sloan-Kettering Cancer Center
Board Certifications:
Medical oncology
Hematology
Clinical Interests:
Medical oncology/hematology
Recent Contributions to PracticeUpdate:
- Intravenous and Oral NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting Among Breast Cancer Patients
- Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer
- Pembrolizumab for Early Triple-Negative Breast Cancer
- Standard Anthracycline-Based vs Docetaxel–Capecitabine in Early High–Clinical and/or –Genomic Risk Breast Cancer
- Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer
- Biosimilars for HER2-Targeted Antibodies
- High-Dose Chemotherapy With HSCT for High-Risk Breast Cancer and Four or More Involved Axillary Lymph Nodes
- Endocrine Therapy ± Whole Breast Irradiation in Low-Risk Breast Cancer Patients After Breast-Conserving Surgery
- Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-Trastuzumab Emtansine
- Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer